Food and Drug Administration Commissioner Marty Makary announced on Monday that his agency is deregulating hormone replacement therapies for menopause patients by calling for manufacturers to remove black box warnings from their products.

Black box warnings are the highest level of caution that the FDA requires for certain potentially dangerous products. Makary, at a press conference Monday, cited several studies touting the benefits of hormone replacement therapy and demonstrating a lack of correlation between HRT and dangerous outcomes such as breast cancer.